Advertisement
Goldman, Sachs & Co. acted as the sole book-running manager of theoffering. Deutsche Bank Securities Inc. acted as co-lead manager and CIBCWorld Markets Corp. acted as co-manager of the offering.
Advertisement
These shares were issued pursuant to an effective shelf registrationstatement. This press release shall not constitute an offer to sell or asolicitation of an offer to buy nor will there be any sale of these securitiesin any state or jurisdiction in which such offer, solicitation or sale wouldbe unlawful prior to registration or qualification under the securities lawsof any such state or jurisdiction. The offering of common stock was made onlyby means of a prospectus, including a prospectus supplement, forming a part ofthe effective registration statement. Printed copies of the final prospectussupplement and base prospectus relating to the offering may be obtained fromGoldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York,New York 10004, Fax: 212-902-9316 or Email at [email protected]).A prospectus supplement relating to the offering has been filed with the SEC,and is available along with the base prospectus filed with the SEC inconnection with the shelf registration, on the SEC's website athttp://www.sec.gov/.
About InterMune
InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.
SOURCE InterMune, Inc.
